作者: Jacob J. Lokich , Henry Sonneborn , Norwood R. Anderson , Murray M. Bern , Frank V. Coco
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2347::AID-CNCR8>3.0.CO;2-8
关键词:
摘要: BACKGROUND Paclitaxel (T), etoposide (E), and cisplatin (P) are each active in gastric carcinoma, either as single agents or part of a multidrug regimen. To the authors' knowledge, combination these three treatment patients with esophageal gastroesophageal carcinoma has not been previously studied. METHODS Previously untreated locally advanced stomach, esophagus, (GE) junction received at least 2 cycles TPE administered twice weekly for 3 weeks, cycle repeated every 28 days. Drug doses, over hours on Monday Thursday Tuesday Friday, consisted T 50 mg/m2/dose, P 15 E 40 mg/m2/dose. For local disease only, subsequent therapy radiation without surgical resection. RESULTS Twenty-five (10) GE (15) were treated. Eighteen had 7 liver metastases presentation. Hematologic toxicity, namely, Grade anemia neutropenia, was experienced by all patients. The median number 4 (range, 2–6). Three evaluable response. All 22 responded; complete responders 19 partial responders. Eleven (6) (5) concomitant 5-fluorouracil, 8 subsequently underwent resection. no tumor surgery, minimal microscopic primary site, lymph node involvement. Twenty-three alive, whom 14 evidence disease. Two metastatic presentation died 9 29 months, respectively. survival 12.5 months 6 to 30+ months). CONCLUSIONS Multifractionated chemotherapy is highly regimen carcinoma. It could be evaluated Phase III trials against other regimens this introduction 5-fluorouracil also an interesting direction explore because its role Cancer 1999;85:2347–51. © 1999 American Society.